We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03329274
Recruitment Status : Recruiting
First Posted : November 1, 2017
Last Update Posted : December 8, 2022
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

The investigators want to understand more about what kinds of health problems are caused by histiocytosis, what happens as a result of different treatments, and how ECD affects people's lives, their feelings and their attitudes. The investigators also want to learn how these things change over time for people with these conditions. To try to figure this out, doctors would like to collect information about people who have histiocytosis and how they are treated for this disease.

Some participants will be asked to complete a brief interview over the telephone. Only a limited number of interviews will take place, and not everyone will be asked to participate in the interview. It is okay if the participant does not want to participate in the interview portion. If this is the case, the participant should let the study team member know when contacted.

Condition or disease
Erdheim-Chester Disease

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 250 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Years
Official Title: Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Actual Study Start Date : October 26, 2017
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : October 2024

Patients with Erdheim-Chester Disease and Other Histiocytoses

Primary Outcome Measures :
  1. Create registry for Erdheim-Chester Disease and Other Histiocytoses [ Time Frame: 3 years ]
    This ECD and Other Histiocytoses registry is motivated to capture comprehensive clinical information as well as patient-centered data about ECD and Other Histiocytoses patients.

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Erdheim-Chester Disease and other HN will be enrolled in this registry study.

Inclusion Criteria:

  • Diagnosis of Erdheim-Chester Disease, Langerhans cell histiocytosis, Rosai Dorfman disease, or another histiocytic neoplasm by either 1) documented histopathologic establishing ECD or HN or 2) documented histopathologic findings compatible with Erdheim-Chester disease or HN in the context of corroborating clinical and/or radiologic findings or 3) documented radiologic findings, in the absence of a biopsy having been performed or yielding evaluable tissue, that are felt by the Principal Investigator to unequivocally represent an ECD/HN diagnosis given the clinical context or 4) self reported with supporting documentation upon medical record collection.
  • Proficiency in English, in the determination of the Investigator or by self report.
  • Willing to have historical and future HN-related health records sent to Registry review.

Exclusion Criteria:

  • Patients unwilling to sign consent.
  • Participants under the age of 18.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03329274

Layout table for location contacts
Contact: Eli Diamond, MD 212-610-0243 diamone1@mskcc.org
Contact: Katherine Panageas, PhD 646-888-8237

Layout table for location information
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Eli Diamond, PhD    212-610-0243      
Contact: Katherine Panageas, MD    646-888-8237      
Principal Investigator: Eli Diamond, MD         
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Layout table for investigator information
Principal Investigator: Eli Diamond, MD Memorial Sloan Kettering Cancer Center
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT03329274    
Other Study ID Numbers: 17-516
First Posted: November 1, 2017    Key Record Dates
Last Update Posted: December 8, 2022
Last Verified: December 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Memorial Sloan Kettering Cancer Center:
Other Histiocytoses
Langerhans cell histiocytosis
Rosai Dorfman disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Erdheim-Chester Disease
Lymphatic Diseases
Histiocytosis, Non-Langerhans-Cell